Over the last two decades there has been a paradigm shift in our perception of cancer therapy. As we know now, neoplasia do not consist only of transformed cells, but contain an abundant and heterogeneous non-transformed component like stromal, endothelial and immune cells. The host immune system can recognize and sometimes react against (pre-) malignant cells as they transform, proliferate and evolve. The knowledge laid the grounds of anticancer immunosurveillance leading to cancer immunotherapy. Recent intense wave of preclinical and clinical investigation culminated in approval of various immunotherapeutic interventions for use in humans. In 2013, the extraordinary clinical success of immunotherapy has won this new method of therapy the title of “Breakthrough of the Year”. Nonetheless, we have just begun to unravel the therapeutic possibilities offered by anticancer immunotherapy.
The following programs have been envisioned to yield a number of Therapeutic and Diagnostic Products and processes
- Development of Tumor Targeting Monoclonal Antibody Therapeutics
- Development of Immunostimulants
- Development of Immunomodulatory Monoclonal Antibody Therapeutics
- Model Mammalian Cell line Development
- Antibody library Generation
Manjula Das, PhD
PhD from Indian Institute of Science with training from McGil University – Canada and MIT-USA during post doctoral studies Manjula has spent long years in the Industry. She is an expert in Biotherapeutics especially critical reagent and assay development (in vitro and in vivo) for regulatory submission of protein drugs. She also has established many companies, the latest being a consultancy firm named Beyond Antibody. Manjula with 20-years long market experience concentrates on translating basic research to products and processes for direct patient care in various areas of cancer.
Kohal Das, PhD
Kohal, a post doctoral fellow, has PhD from IISc. At MSCTR he works on the role of Insulin receptor in solid tumors. Kohal concentrates on development of novel platforms for deciphering Insulin receptor function.
Charitha G S, PhD
Charitha, a post doctoral fellow, has PhD from CDFD, Hyderabad. At MSCTR she works on development of cell based model from patient samples. Currently, she is concentrating on making Oral cancer cell lines important to understand the immune profile of the tumor.
Nehanjali Dwivedi, MSc
Nehanjali works on the role of specificinflammatory biomarkers in failure of Immune-surveillance in Cancer. She is developing a few multiplexed diagnostic systems to perform an epidemiological study to correlate inflammation, immune surveillance and Cancer.
Mohit Srivastava, PG Biotechnology
Mohit Srivastava, an ICMR JRF works on the role of Insulin Receptor in cancer. Mohit is trying to establish the correlation between the type of Insulin receptor and type of cancer.
C.A. Divya, MSc
Divya works on specific Inflammatory biomarkers common to Diabetes and Cancer. She is trying to suppressthe markers with monoclonal antibody treatment and studying the development of diabetes and cancerin treated and untreated animal model.
Madhumathi H K, M.Tech
Junior Research Fellow
Madhumathi works on assay development for the Biopharma Industry in an Industry funded project. Since the laboratory is developing various biotherapeutic and diagnostic products, multiple assay platforms are necessary to check the efficacy and safety of the products.
Neha Dhar, PhD
Post Doctoral Fellow
Neha, worked as a post doctoral fellow in the tumor Immunology Program and has a PhD from IISc. She is an expert in stable cell line development and her interests are in structure-function relationship of proteins.